Prolonged cholestasis following endoscopic retrograde cholangiopancreatography, a rare complication of contrast agent induced liver injury: A case report and literature review

Medicine (Baltimore). 2020 Jan;99(3):e18855. doi: 10.1097/MD.0000000000018855.

Abstract

Rationale: Prolonged cholestasis is a rare complication associated with endoscopic retrograde cholangiopancreatography (ERCP).

Patient concerns: A 68-year-old man who presented with worsening cholestasis after ERCP for the removal of a common bile duct stone.

Diagnosis: Total bilirubin increased up to 35.2 mg/dL after the 21st day post-ERCP. A percutaneous liver biopsy was performed and drug-related cholestasis was suspected as occurring as a result of the contrast agent.

Interventions: Oral ursodeoxycholic acid and cholestyramine were prescribed to the patient.

Outcomes: By the 7th week post-ERCP, the patient's symptoms and markers of physiological health began to resolve. The bilirubin returned to normal levels on the 106th day post-ERCP. We reviewed the literature for studies of 9 patients with jaundice more than 30 days post-ERCP, the peak of total serum bilirubin occurred on 16th ± 7th days and the recovery followed after mean time of 54th ± 22th days.

Lessons: Although the cholestasis was prolonged, the outcome was favorable after medical therapy. There were no long-term consequences for the patient.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Aged
  • Cholagogues and Choleretics / therapeutic use
  • Cholangiopancreatography, Endoscopic Retrograde*
  • Cholestasis / chemically induced*
  • Cholestasis / drug therapy
  • Cholestyramine Resin / therapeutic use
  • Contrast Media / adverse effects*
  • Drug Therapy, Combination
  • Humans
  • Male
  • Ursodeoxycholic Acid / therapeutic use

Substances

  • Cholagogues and Choleretics
  • Contrast Media
  • Cholestyramine Resin
  • Ursodeoxycholic Acid